| P50 | author | Baha Sibai | Q100559638 |
| P2093 | author name string | Michael Kupferminc | |
| | Gus Dekker | |
| P2860 | cites work | Thrombophilia and pregnancy | Q24801115 |
| | Primary, secondary, and tertiary prevention of pre-eclampsia | Q28176253 |
| | Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis | Q28191497 |
| | Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study | Q61836418 |
| | Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta | Q61865493 |
| | Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants | Q69685000 |
| | Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae | Q69874741 |
| | Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease | Q71284666 |
| | Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells | Q73047123 |
| | Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction | Q73341185 |
| | Immunohistochemical study of annexin V expression in placentae of preeclampsia | Q73341311 |
| | Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis | Q73449672 |
| | Trial of Calcium to Prevent Preeclampsia | Q73485563 |
| | Abortion, changed paternity, and risk of preeclampsia in nulliparous women | Q73500722 |
| | Hypertensive disorders in twin versus singleton gestations. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units | Q73675281 |
| | Chronic hypertension in pregnancy | Q74548998 |
| | Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia | Q75355739 |
| | Obesity and preeclampsia: the potential role of inflammation | Q77156957 |
| | Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation | Q77543305 |
| | Prevention of preeclampsia: a big disappointment | Q77580496 |
| | Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia | Q77731627 |
| | Maternal periodontal disease is associated with an increased risk for preeclampsia | Q78952398 |
| | Is pre-eclampsia more than one disease? | Q79752866 |
| | Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. | Q47889241 |
| | Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia | Q47945074 |
| | Increased breath markers of oxidative stress in normal pregnancy and in preeclampsia | Q47976187 |
| | Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 |
| | Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies | Q48608775 |
| | Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. | Q51027382 |
| | The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. | Q52003519 |
| | High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. | Q54096102 |
| | Color Doppler imaging of the uteroplacental circulation in the first trimester: value in predicting pregnancy failure or complication. | Q54173695 |
| | Implantation: can immunological parameters of implantation failure be of interest for pre-eclampsia? | Q54762432 |
| | The Interval between Pregnancies and the Risk of Preeclampsia | Q57420054 |
| | Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial | Q57624866 |
| | Risk for subsequent coronary artery disease after preeclampsia | Q57671378 |
| | Could an infectious trigger explain the differential maternal response to the shared placental pathology of preeclampsia and normotensive intrauterine growth restriction? | Q58623947 |
| | Low-Dose Aspirin to Prevent Preeclampsia in Women at High Risk | Q61835495 |
| | Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia | Q28192233 |
| | Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas | Q28192580 |
| | Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias | Q28193116 |
| | Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review | Q28196410 |
| | Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation | Q28208821 |
| | Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 |
| | How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview | Q30841551 |
| | Microvascular dysfunction: a link between pre‐eclampsia and maternal coronary heart disease | Q31021082 |
| | Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy | Q33200520 |
| | Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States | Q33349406 |
| | Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count | Q33360652 |
| | Fortnightly review: management of hypertension in pregnancy | Q33633498 |
| | Expectant management of severe preeclampsia remote from term | Q33714163 |
| | Fetal and maternal contributions to risk of pre-eclampsia: population based study | Q33783098 |
| | Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? | Q33811293 |
| | The detection, investigation and management of hypertension in pregnancy: executive summary | Q33990736 |
| | Genetic conflicts in human pregnancy | Q34060435 |
| | The annexinopathies: a new category of diseases | Q34100142 |
| | Uterine natural killer cells: insights into their cellular and molecular biology from mouse modelling | Q34258287 |
| | Uterine spiral artery remodeling involves endothelial apoptosis induced by extravillous trophoblasts through Fas/FasL interactions. | Q34492106 |
| | How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review | Q34501896 |
| | Sperm exposure and development of preeclampsia | Q34533665 |
| | Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 |
| | Eclampsia in the United Kingdom. | Q34722815 |
| | Pre-eclampsia: more than pregnancy-induced hypertension | Q34726951 |
| | Natural killer cells and pregnancy | Q34810250 |
| | Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study | Q34950435 |
| | Transforming growth factor beta--a mediator of immune deviation in seminal plasma | Q34973790 |
| | Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis | Q34977059 |
| | Fetal cells and cell-free fetal DNA in maternal blood: new insights into pre-eclampsia | Q35033080 |
| | Expectant management of severe preeclampsia and preeclampsia superimposed on chronic hypertension between 24 and 34 weeks' gestation | Q35068952 |
| | Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia | Q35079406 |
| | Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. | Q35096089 |
| | Pre-eclampsia, the placenta and the maternal systemic inflammatory response--a review | Q35169648 |
| | Diagnosis and management of gestational hypertension and preeclampsia | Q35173115 |
| | The genetics of pre-eclampsia: a feto-placental or maternal problem? | Q35177399 |
| | Trophoblast deportation and the maternal inflammatory response in pre-eclampsia | Q35190881 |
| | Th1/Th2 balance in preeclampsia | Q35190885 |
| | The birth interval hypothesis-does it really indicate the end of the primipaternity hypothesis | Q35190895 |
| | The developmental origins of well-being | Q35214145 |
| | The confidential enquiry into maternal and child health (CEMACH). | Q35274715 |
| | Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis | Q35566921 |
| | Pre-eclampsia and the hypertensive disorders of pregnancy | Q35623562 |
| | Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials | Q35851213 |
| | Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction | Q35888435 |
| | World Health Organization systematic review of screening tests for preeclampsia | Q35968177 |
| | Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success | Q36399286 |
| | Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families | Q37205410 |
| | Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? | Q37366512 |
| | Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns | Q40524863 |
| | Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: evidence for an increased sensitivity to Fas-mediated apoptosis | Q40652949 |
| | Preeclampsia: an excessive maternal inflammatory response to pregnancy | Q40824430 |
| | Etiology and pathogenesis of preeclampsia: current concepts | Q40835002 |
| | Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications | Q41243028 |
| | The parent-of-origin effect of 10q22 in pre-eclamptic females coincides with two regions clustered for genes with down-regulated expression in androgenetic placentas | Q42629757 |
| | Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia | Q43694674 |
| | Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women | Q43705726 |
| | Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia | Q43718487 |
| | Outcomes in young adulthood for very-low-birth-weight infants. | Q43858188 |
| | Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. | Q43982505 |
| | Platelets and the beginnings of preeclampsia | Q44244911 |
| | Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia | Q44434565 |
| | A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia | Q44606809 |
| | Severe preeclampsia is associated with high inhibin A levels and normal leptin levels at 7 to 13 weeks into pregnancy. | Q44717981 |
| | Fetal inherited thrombophilias influence the severity of preeclampsia, IUGR and placental abruption | Q44809425 |
| | Late postpartum eclampsia: a preventable disease? | Q44831228 |
| | Association of rheumatologic disease with preeclampsia | Q44874760 |
| | Random urine protein-creatinine ratio to predict proteinuria in new-onset mild hypertension in late pregnancy | Q45005723 |
| | Paternal and maternal components of the predisposition to preeclampsia | Q45084472 |
| | Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation | Q46346347 |
| | Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial | Q46351253 |
| | Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group | Q46355603 |
| | Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. | Q46356669 |
| | Temporising management of severe pre-eclampsia with and without the HELLP syndrome | Q46362894 |
| | Membrane-bound HLA-G activates proliferation and interferon-gamma production by uterine natural killer cells | Q47189403 |
| | Circulating angiogenic factors and the risk of preeclampsia | Q47217679 |
| | Delayed postpartum preeclampsia: an experience of 151 cases | Q47597799 |
| | Maternal morbid obesity and the risk of adverse pregnancy outcome | Q47861917 |
| | Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia | Q47889158 |
| P433 | issue | 9461 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| P304 | page(s) | 785-799 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Pre-eclampsia | |
| P478 | volume | 365 | |